Nuvation Bio Inc. (NUVB) Stock Analysis
Healthcare · Biotechnology · NYSE
Nuvation Bio Inc. (NUVB) posted $62.90M in revenue for fiscal 2025 (up 699.0% year over year), with a net loss of $204.63M, per its SEC filings.
Data last refreshed August 2, 2026 from SEC filings · how we compute this
The analyst's take on Nuvation Bio Inc.
Nuvation Bio Inc. has grown revenue from $0 to $62.90M over the last 6 fiscal years. The most recent year was up 699%.
Net margin sits at -325.3%, up 6888.5 points year over year on a 85.2% gross margin. It carries about $52.93M of total debt.
The one thing worth a second look in the filings is share count rising (dilution).
Synthesised from Nuvation Bio Inc.'s SEC filings — descriptive, not advice. Ask the analyst your own question →
Nuvation Bio Inc. revenue & earnings — last 6 fiscal years
| Metric | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $7.87M | $62.90M |
| Gross profit | — | — | — | — | $795,000 | $53.60M |
| Net income | $-41.66M | $-86.85M | $-104.20M | $-75.80M | $-567.94M | $-204.63M |
| Net margin | — | — | — | — | -7213.8% | -325.3% |
Source: Nuvation Bio Inc. SEC filings (10-K).
Nuvation Bio Inc.: 3 potential red flags in the filings
Patterns in the filed statements worth a second look — computed and cited, not AI guesswork, and not a signal to sell. The kind of thing that hides in a 10-K.
- Share count rising (dilution)Shares outstanding grew 59.0% over 4 years (217.9M → 346.5M) — existing holders' stakes are being diluted.
- Debt with negative operating cash flowCarries $58.7M of debt while last year's operating cash flow was negative ($-173.4M).
- Currently unprofitableThe latest fiscal year was a net loss (net margin -325.3%).
Explore 6 years of Nuvation Bio Inc. financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track NUVB in your portfolio →
Nuvation Bio Inc. financial history by metric
About Nuvation Bio Inc.
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on developing product candidates for cancer treatment. The company's lead product candidate is IBTROZI (taletrectinib), a ROS1 inhibitor for the treatment of patients with ROS1+ non-small cell lung cancer. It is also developing Safusidenib, an inhibitor of mutant isocitrate dehydrogenase 1 in phase 3 clinical trials for the maintenance treatment of high-risk or high-grade IDH1-mutant astrocytoma with safusidenib against placebo. The company was founded in 2018 and is headquartered in New York, New York.
Nuvation Bio Inc. — frequently asked questions
What is Nuvation Bio Inc.'s revenue?
Nuvation Bio Inc. (NUVB) reported revenue of $62.90M for fiscal year 2025, up 699.0% from the prior year, according to its SEC filings.
Is Nuvation Bio Inc. profitable?
No — NUVB reported a net loss of $-204.63M in fiscal 2025.
What is NUVB's P/E ratio?
Nuvation Bio Inc. trades at a price-to-earnings ratio of about 0.0 based on the latest data in our nightly-refreshed cache.
How much debt does Nuvation Bio Inc. have?
As of fiscal year 2025, NUVB carried roughly $52.93M in total debt (short- plus long-term borrowings), per its filed balance sheet.
What is Nuvation Bio Inc.'s gross margin?
NUVB's gross margin was 85.2% in fiscal 2025 — gross profit of $53.60M on revenue of $62.90M.
What is Nuvation Bio Inc.'s market cap?
Nuvation Bio Inc. (NUVB) has a market capitalization of about $1.64B, based on the latest data in our nightly-refreshed cache.
When does Nuvation Bio Inc.'s fiscal year end?
NUVB's fiscal year ends in December. Its most recent annual filing covers the fiscal year ending 2025-12-31.
Where does this data come from?
All figures are computed from Nuvation Bio Inc.'s official SEC filings (10-K and 10-Q), covering 6 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.